Dimerix Ltd has released a press release.
Dimerix Raises $2 million to Advance Clinical Program
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Dimerix
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
- Appointment of Chief Executive Officer
- Update presentation - interim data
- Positive interim analysis of DMX-200 phase II data
- Appendix 4E
Later from Dimerix
- Key Patent Allowed in Japan
- Corporate Presentation
- Receipt of $420k Research & Development Tax Refund
- Investor Update
- Research Validates Relevance of DMX Receptor-HIT Technology
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix